Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations

Management of LN in China showed poor alignment with the 2023 EULAR recommendations regarding initial and adjusted therapy, as well as renal biopsy. The improvement of LN management requires both the patients and the rheumatologists to work together. Key Points • To the best of our knowledge, this is the first real-world implementation study of LN in China. This is also the first real-world implementation study for the newly updated EULAR 2023 recommendation for SLE. • We not only examined the consistency between LN management in China and EULAR recommendations, but also identified potential factors associated with the implementation of the recommendations. • We believe that our study makes a significant contribution to the management of LN.

Authors

Institutions

Publication Details

Journal
Clinical Rheumatology
Published
2025-06-07
DOI
https://doi.org/10.1007/s10067-025-07520-x
Citations
1
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
1.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations

Xiaomei Leng, Jiuliang Zhao, Xinping Tian, Xinwang Duan et al.
1 citations
Clinical Rheumatology
Systemic Lupus Erythematosus Research
1.67
article

Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations

Xiaomei Leng, Jiuliang Zhao, Xinping Tian, Xinwang Duan, Shangyi Jin, Yunzhuan Chen, Chanyuan Wu, Wei Bai, Jia Liu, Lijun Wu, Wei Wei, Hongbin Li, Qian Wang, Shengyun Liu, Xiaofeng Zeng, Yinli Gui, Yanhong Wang
article en
1 citations

Abstract

Management of LN in China showed poor alignment with the 2023 EULAR recommendations regarding initial and adjusted therapy, as well as renal biopsy. The improvement of LN management requires both the patients and the rheumatologists to work together. Key Points • To the best of our knowledge, this is the first real-world implementation study of LN in China. This is also the first real-world implementation study for the newly updated EULAR 2023 recommendation for SLE. • We not only examined the consistency between LN management in China and EULAR recommendations, but also identified potential factors associated with the implementation of the recommendations. • We believe that our study makes a significant contribution to the management of LN.

Clinical RheumatologyVol. 44(7)
Nanchang University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), Tianjin Medical University General Hospital (CN), Second Affiliated Hospital of Nanchang University (CN), People's Hospital of Xinjiang Uygur Autonomous Region (CN), Henan Provincial People's Hospital (CN), Zhengzhou People's Hospital (CN), First Affiliated Hospital of Henan University (CN), First Affiliated Hospital of Zhengzhou University (CN), Beijing Chaoyang Emergency Medical Center (CN), Fuyang Second People's Hospital (CN), Inner Mongolia Medical University (CN)
National Natural Science Foundation of China, Peking Union Medical College Hospital
Openalex Percentile: Top 16%
Systemic Lupus Erythematosus Research
1.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.